Blood plasma-based drug against COVID-19 successfully passes clinical trials

… received a permanent certification by the Russian Health Ministry

… confirmed its efficacy, safety and the ability to neutralize the coronavirus

… on the basis of the blood plasma of individuals who had been infected with COVID-19

… contains antibodies to the virus

… prevents the disease from taking on a more severe form and helps fight the infection

… double-blind placebo-controlled …the risk of developing a more severe form of the disease decreased

… most effective at the early stages of the disease

… In 70% of cases, therapy prevented the development of such complications

… as a cytokine storm, kidney failure, thromboembolic complications

… the development of acute respiratory distress syndrome, extensive lung damage or worsened clinical symptoms

… The first preparation of the specific anti-COVID immunoglobulin worldwide has successfully passed … proving its safety and efficacy

 

Share: